QNTM
Quantum Biopharma Ltd. Class B Subordinate Voting SharesQNTM
QNTM
About: Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
Employees: 8
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
34% more capital invested
Capital invested by funds: $192K [Q3] → $256K (+$64.4K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.06% less ownership
Funds ownership: 3.7% [Q3] → 3.63% (-0.06%) [Q4]
25% less funds holding
Funds holding: 12 [Q3] → 9 (-3) [Q4]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for QNTM.
Financial journalist opinion
Neutral
Newsfile Corp
3 hours ago
Quantum BioPharma Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.
Neutral
Newsfile Corp
1 week ago
Quantum BioPharma Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 7, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.
Neutral
GlobeNewsWire
1 month ago
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“MZ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.
Neutral
GlobeNewsWire
1 month ago
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of Enterprise Canada Inc. (“Enterprise”) and Empire Market Ventures, LLC (“Empire”) (together, the “Agencies”) to lead its comprehensive public relations and investor awareness programs, respectively, across all key markets.
Neutral
GlobeNewsWire
1 month ago
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
QUANTUM BIOPHARMA PARTNER CELLY NUTRITION RETAINS LEADING NEW YORK INVESTMENT BANK TO ADVISE ON CAPITAL RAISE AND POSSIBLE INITIAL PUBLIC OFFERING FOLLOWIN
Neutral
GlobeNewsWire
1 month ago
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover
Neutral
Accesswire
1 month ago
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
Awards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it will be back in the Ontario Superior Court of Justice on January 24, 2025.
Neutral
Accesswire
2 months ago
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App TORONTO, ON / ACCESSWIRE / January 14, 2025 / Quantum BioPharma Ltd.
Neutral
Accesswire
2 months ago
Quantum Biopharma Ltd. Approved to Dual List on Upstream
Trading to become available January 14th under 'QNTM' TORONTO, ONTARIO / ACCESSWIRE / January 7, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app.
Neutral
Accesswire
2 months ago
Quantum Biopharma Announces Closing of Second Tranche
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it has closed a second tranche ("Second Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") and has issued 500 Debenture Units (as defined in the December 5 NR) for $500,000.
Charts implemented using Lightweight Charts™